ArticleInternal medicine (Tokyo, Japan)2026

Successful Tepotinib Rechallenge after Tepotinib-induced Adverse Events Following Pembrolizumab Failure in a Case of Non-small Cell Lung Carcinoma with MET Exon 14 Skipping.

Yuichiro Yasuda et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.